IMRN: Immuron Ltd.
About
Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. Its proprietary technology is based on polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum. This technology can be used to target viruses or bacteria and neutralize the toxins they produce on mucosal surfaces. It operates through the Research and Development, and Hyperimmune Products segments. The Research and Development segment includes projects performed in Australia and United States. The Hyperimmune Products segment is composed of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994, and is headquartered in Carlton, Australia.
Current Value
$1.861 Year Return
Current Value
$1.861 Year Return
Key Details
Market Cap
$10.94M
P/E Ratio
-2.39
1Y Stock Return
6.06%
1Y Revenue Growth
164.30%
Dividend Yield
0.00%
Price to Book
1.3
Strategies that include IMRN
Stock's related to IMRN
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| AGR | 57.65% | $14.02B | +14.76% | 4.86% |
| OSPN | 45.82% | $671.30M | +76.17% | 0.00% |
| KR | 42.80% | $42.38B | +33.68% | 2.07% |
| EHAB | 42.37% | $375.62M | -26.04% | 0.00% |
| RTO | 41.29% | $12.87B | -9.47% | 2.26% |
| WLY | 41.21% | $2.77B | +68.65% | 2.73% |
| BJ | 35.09% | $12.30B | +41.06% | 0.00% |
| REPX | 31.90% | $770.59M | +34.50% | 4.06% |
| HNST | 30.74% | $772.35M | +306.91% | 0.00% |
| NMM | 30.39% | $1.55B | +121.75% | 0.39% |
| NVO | 30.02% | $342.62B | -0.61% | 1.39% |
| ML | 29.35% | $890.76M | +133.94% | 0.00% |
| GPRK | 26.73% | $423.11M | -12.86% | 8.50% |
| KFRC | 23.46% | $1.12B | -7.67% | 0.64% |
| ARHS | 23.30% | $1.35B | +11.23% | 0.00% |
| BYRN | 23.23% | $456.55M | +279.63% | 0.00% |
| AZPN | 23.17% | $15.72B | +34.64% | 0.00% |
| CR | 22.80% | $10.48B | +70.24% | 0.43% |
| SEMR | 22.51% | $2.17B | +50.31% | 0.00% |
| DSGX | 22.48% | $9.77B | +41.08% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CPSH | -47.29% | $21.21M | -39.42% | 0.00% |
| VSCO | -43.09% | $2.75B | +65.97% | 0.00% |
| TPVG | -41.04% | $272.08M | - | 18.59% |
| CDMO | -37.13% | $783.46M | +125.18% | 0.00% |
| CIEN | -34.81% | $9.85B | +49.04% | 0.00% |
| MEI | -34.07% | $342.58M | -58.85% | 5.72% |
| HDSN | -33.64% | $272.55M | -52.44% | 0.00% |
| ADT | -25.95% | $6.84B | +26.94% | 2.64% |
| INFN | -22.33% | $1.57B | +57.01% | 0.00% |
| PSFE | -21.50% | $1.06B | +52.84% | 0.00% |
| HPK | -19.55% | $1.96B | -3.85% | 0.78% |
| TTC | -17.62% | $8.60B | +0.47% | 1.70% |
| CRC | -16.45% | $5.46B | +16.46% | 2.21% |
| KGS | -15.17% | $3.59B | +124.19% | 3.85% |
| ALNT | -13.72% | $414.73M | -6.60% | 0.49% |
| HUYA | -13.63% | $227.88M | +13.56% | 0.00% |
| CBOE | -13.62% | $22.09B | +17.17% | 1.08% |
| CME | -13.42% | $81.64B | +7.34% | 2.00% |
| VKTX | -13.15% | $5.75B | +346.63% | 0.00% |
| TLPH | -12.94% | $11.91M | +9.27% | 0.00% |
ETF's related to IMRN
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| QQA | 23.29% | $135.25M | 0% |
| FLBL | 21.61% | $647.33M | 0.45% |
| EFAA | 21.43% | $116.17M | 0% |
| RSPA | 20.76% | $272.75M | 0% |
| PFFV | 20.10% | $257.51M | 0.25% |
| URNM | 17.58% | $1.71B | 0.75% |
| URA | 16.75% | $3.90B | 0.69% |
| FPEI | 16.19% | $1.49B | 0.85% |
| IDHQ | 16.09% | $360.15M | 0.29% |
| EWN | 15.51% | $244.85M | 0.5% |
| DMXF | 15.23% | $769.64M | 0.12% |
| IEV | 15.09% | $1.61B | 0.61% |
| IQLT | 15.04% | $7.74B | 0.3% |
| BBEU | 14.82% | $6.43B | 0.09% |
| DUSB | 14.81% | $812.64M | 0.15% |
| URNJ | 14.59% | $309.81M | 0.8% |
| IEUR | 14.30% | $4.18B | 0.11% |
| MXI | 14.25% | $225.53M | 0.42% |
| VIGI | 14.24% | $7.05B | 0.15% |
| GLOV | 14.17% | $1.04B | 0.25% |
News
Yahoo
MELBOURNE, Australia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented early this morning at the 21st Virtual Investor Summit Microcap Event (November 21, US Eastern Time). A copy of the presentation is available on the Company’s website. https://www.immuron.com.au/corporate-presentations/ This release has been authorised by the directors of Immuron Limited. COMPANY CONTACT: Steven LydeamoreChi
Yahoo
MELBOURNE, AUSTRALIA / ACCESSWIRE / November 18, 2024 /Immuron Limited (NASDAQ:IMRN) has one commercial product and two pipeline assets in three clinical programs for the treatment of gut mediated diseases. The company will be available for 1-on-1 ...
Yahoo
MIAMI, Oct. 29, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 76th Emerging Growth Conference on October 30 & 31, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting comp
Yahoo
MELBOURNE, Australia, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be participating in a fireside chat at the Maxim Virtual Healthcare Conference on Wednesday, 16th October 2024 (4.30pm U.S. Eastern time). A copy of the presentation covering information being discussed is available on the Company’s website. https://www.immuron.com.au/corporate-presentations/ This release has been authorised by t
Yahoo
Sales Highlights: Global• September 2024 Quarter AUD$1.5 million up 13% on prior quarter Australia• September 2024 Quarter AUD$1.0 million up 3% on prior quarter NorthAmerica• September 2024 Quarter AUD$0.5 million up 48% on prior quarter MELBOURNE, Australia, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued strong sales growth (unaudited) of Travelan®, an over-the-co
Yahoo
MELBOURNE, Australia, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), is an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases. Following discussion with the US Naval Medical Research Command (NMRC), today the Company can announce that the NMRC has completed the interim analysis for the clinical evaluation of a new oral therapeutic t
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.